| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Medicine Branch, National Cancer Institute, Bethesda, Maryland 20892
A mitoxantrone-resistant human MCF-7 breast cancer subline (MCF/MX) which is approximately 4000-fold resistant to mitoxantrone was isolated by serial passage of the parental wild-type MCF-7 cells (MCF/WT) in stepwise increasing concentrations of drug. MCF/MX cells were also approximately 10-fold cross-resistant to doxorubicin and etoposide but were not cross-resistant to vinblastine. Intracellular accumulation of radiolabeled mitoxantrone was markedly reduced in MCF/MX cells relative to that in the drug-sensitive MCF/WT cells. This decrease in intracellular drug accumulation into MCF/MX cells was associated with enhanced drug efflux, which was reversed when cells were incubated in the presence of sodium azide and 2, 4-dinitrophenol, suggesting an energy-dependent process. Incubation of MCF/MX cells with verapamil did not affect either the accumulation of mitoxantrone or the level of resistance in these cells. Furthermore, RNase protection and Western blot analyses failed to detect the expression of the mdr1 RNA or P-glycoprotein, a drug efflux pump known to be associated with the development of multidrug resistance in vitro. However, a polyclonal antibody directed against a synthetic peptide corresponding to the putative ATP binding domain of P-glycoprotein reacted with two (Mr 42,000 and 85,000) membrane proteins from MCF/MX cells which were not found in MCF/WT. Functional assays and Western blot analysis for topoisomerase II revealed no differences in topoisomerase II activity or protein levels in MCF/MX cells. Thus, resistance in this cell line is apparently associated with enhanced drug efflux involving a pathway distinct from the mdr1-encoded multidrug transporter P-glycoprotein.
1 To whom requests for reprints should be addressed, at Building 10, Room 12N226, National Cancer Institute, Bethesda, MD 20892.
Received 9/ 5/91. Accepted 9/ 9/92.
This article has been cited by other articles:
![]() |
S. Kasibhatla, V. Baichwal, S. X. Cai, B. Roth, I. Skvortsova, S. Skvortsov, P. Lukas, N. M. English, N. Sirisoma, J. Drewe, et al. MPC-6827: A Small-Molecule Inhibitor of Microtubule Formation That Is Not a Substrate for Multidrug Resistance Pumps Cancer Res., June 15, 2007; 67(12): 5865 - 5871. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. S. Morrow, C. Peklak-Scott, B. Bishwokarma, T. E. Kute, P. K. Smitherman, and A. J. Townsend Multidrug Resistance Protein 1 (MRP1, ABCC1) Mediates Resistance to Mitoxantrone via Glutathione-Dependent Drug Efflux Mol. Pharmacol., April 1, 2006; 69(4): 1499 - 1505. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Nakamura, M. Oka, H. Soda, K. Shiozawa, M. Yoshikawa, A. Itoh, Y. Ikegami, J. Tsurutani, K. Nakatomi, T. Kitazaki, et al. Gefitinib ("Iressa", ZD1839), an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses Breast Cancer Resistance Protein/ABCG2-Mediated Drug Resistance Cancer Res., February 15, 2005; 65(4): 1541 - 1546. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. L. Volk and E. Schneider Wild-Type Breast Cancer Resistance Protein (BCRP/ABCG2) is a Methotrexate Polyglutamate Transporter Cancer Res., September 1, 2003; 63(17): 5538 - 5543. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. C. Lockhart, R. G. Tirona, and R. B. Kim Pharmacogenetics of ATP-binding Cassette Transporters in Cancer and Chemotherapy Mol. Cancer Ther., July 1, 2003; 2(7): 685 - 698. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Wang, T. Furukawa, T. Nitanda, M. Okamoto, Y. Sugimoto, S.-I. Akiyama, and M. Baba Breast Cancer Resistance Protein (BCRP/ABCG2) Induces Cellular Resistance to HIV-1 Nucleoside Reverse Transcriptase Inhibitors Mol. Pharmacol., January 1, 2003; 63(1): 65 - 72. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. L. Volk, K. M. Farley, Y. Wu, F. Li, R. W. Robey, and E. Schneider Overexpression of Wild-Type Breast Cancer Resistance Protein Mediates Methotrexate Resistance Cancer Res., September 1, 2002; 62(17): 5035 - 5040. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kim, H. Turnquist, J. Jackson, M. Sgagias, Y. Yan, M. Gong, M. Dean, J. G. Sharp, and K. Cowan The Multidrug Resistance Transporter ABCG2 (Breast Cancer Resistance Protein 1) Effluxes Hoechst 33342 and Is Overexpressed in Hematopoietic Stem Cells Clin. Cancer Res., January 1, 2002; 8(1): 22 - 28. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. L. Volk, K. Rohde, M. Rhee, J. J. McGuire, L. A. Doyle, D. D. Ross, and E. Schneider Methotrexate Cross-Resistance in a Mitoxantrone-selected Multidrug-resistant MCF7 Breast Cancer Cell Line Is Attributable to Enhanced Energy-dependent Drug Efflux Cancer Res., July 1, 2000; 60(13): 3514 - 3521. [Abstract] [Full Text] |
||||
![]() |
T Litman, M Brangi, E Hudson, P Fetsch, A Abati, D. Ross, K Miyake, J. Resau, and S. Bates The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2) J. Cell Sci., January 6, 2000; 113(11): 2011 - 2021. [Abstract] [PDF] |
||||
![]() |
Z.-S. Chen, T. Furukawa, T. Sumizawa, K. Ono, K. Ueda, K. Seto, and S.-I. Akiyama ATP-Dependent Efflux of CPT-11 and SN-38 by the Multidrug Resistance Protein (MRP) and Its Inhibition by PAK-104P Mol. Pharmacol., May 1, 1999; 55(5): 921 - 928. [Abstract] [Full Text] |
||||
![]() |
D. D. Ross, W. Yang, L. V. Abruzzo, W. S. Dalton, E. Schneider, H. Lage, M. Dietel, L. Greenberger, S. P. C. Cole, and L. A. Doyle Atypical Multidrug Resistance: Breast Cancer Resistance Protein Messenger RNA Expression in Mitoxantrone-Selected Cell Lines J Natl Cancer Inst, March 3, 1999; 91(5): 429 - 433. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Hazlehurst, N. E. Foley, M. C. Gleason-Guzman, M. P. Hacker, A. E. Cress, L. W. Greenberger, M. C. De Jong, and W. S. Dalton Multiple Mechanisms Confer Drug Resistance to Mitoxantrone in the Human 8226 Myeloma Cell Line Cancer Res., March 1, 1999; 59(5): 1021 - 1028. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |